News, Information,

Resources, Sales


  Exact Time






Custom Search


   TRIGONOMETRY101 Custom Search on Anything! - Try it now!
  Get a job today!  1000s of Jobs!   Click on any job:  

Mainframes Jobs


COBOL, SysProg, ASM,

Proj Mgrs, QA, Support

Software101 Jobs

JAVA, .NET, C++, C#


Internet, Web dev

 FIRE101 Jobs

Firemen, Volunteer,

EMT, EMS, Emergency,

Firefighters, Chief

 POLICE101 Jobs

Police Officers, Cops

Law Enforcement,

Paralegal, Forensics


Lab Techs, Interns,

Genetics Research, Medical

Genetics Counselor, Biotech

 Nursing101 Jobs

Clinical, Emergency, ICU

LPN, RN, Travel, Home

Nurse Practitioners







    * Latest "Endpoints" News * 


UPDATED: India's generic drug maker Glenmark draws up a US-based branded drugs unit  Endpoints News

Israel's Teva — the world's largest generic drugmaker — isn't the only one looking to capitalize on branded drugs. Indian generic drug manufacturer Glenmark is ...

An update on the Endpoints business model — and how your company can directly support it  Endpoints News

Pictured: The print-optimized version of Endpoints' 2018 New Drug Approvals report. All paid subscribers will receive a direct link to download the PDF.

Canaan leaps into UK biotech by co-leading $14M Series A for immuno-oncology upstart Grey Wolf  Endpoints News

Checkpoint inhibitors have done wonders for immuno-oncology, but the potent class of drugs doesn't work across all cancers. To remedy this, UK-based biotech ...

FDA experts offer a big thumbs up for J&J's flawed application for ketamine-based depression drug — but trial failures, safety questions spur concerns  Endpoints News

J&J may have a deeply flawed application for its new/old drug to treat major depression, but the researchers who turned out to present the case for esketamine ...

Potential Metastatic Prostate Cancer Therapy Achieves Primary Trial Endpoints  Specialty Pharmacy Times

Janssen's apalutamide (Erleada) met its dual primary endpoints in the phase 3 TITAN study evaluating the drug in metastatic castration-sensitive prostate cancer ...

2019's second unicorn Gossamer raises $276M in upsized IPO offering, MPM's Harpoon makes its Nasdaq debut with $75.6M bounty  Endpoints News

Meet 2019's newest biotech unicorn — Gossamer Bio — which is making its debut on Nasdaq Friday with an upsized $276 million offering. The drug developer ...

Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech  Endpoints News

Sangamo {$SGMO} today released the first snapshots from two early-stage studies looking at the effect their first-generation gene editing technology has on two ...

Encouraging gene therapy data give uniQure an injection of confidence as it preps PhIII showdown with Spark  Endpoints News

Gene therapy company uniQure started the week in style with the news that it's dosed the first patient in its Phase III trial — a crucial step toward its quest for the ...

Zai Lab nabs speedy China regulatory review for PARP drug Zejula  Endpoints News

Chinese regulatory officials are signaling that they're ready to whisk Zejula through the regulatory process. Zai Lab $ZLAB said this morning that the Center for ...

TG Therapeutics' shares jump as umbralisib wins FDA's breakthrough status  Endpoints News

About a month after the publication of encouraging results from an early-stage study evaluating J&J's Imbruvica in combination with its experimental drug ...

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin — shares rocket higher  Endpoints News

MacroGenics $MGNX has claimed success in their Phase III trial of their drug margetuximab for metastatic breast cancer, putting them on the path to a BLA filing.

Rituximab Biosimilar Candidate Met Phase 1/3 Endpoints  MD Magazine

ABP 798, a biosimilar candidate for rituximab, met pharmacokinetic, efficacy, and safety endpoints in a trial among participants with rheumatoid arthritis.

Osimertinib shows 'consistent improvement' in post-progression endpoints for non-small cell lung cancer  Healio

First-line osimertinib compared favorably to standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated ...

EMA says symbolic goodbye to London HQ as it sets up shop in Amsterdam  Endpoints News

Europe's medicines regulator, having been based in London since 1995, is gearing up for its move to Amsterdam as Westminster's uncertainty regarding Brexit ...

Evolus celebrates greenlight for Botox rival while Allergan counterattacks with a complaint of stolen trade secrets  Endpoints News

Despite a months-long delay, Evolus has overcome manufacturing faults FDA previously found and managed to secure a nod to begin marketing its Botox rival.

     Internet Search Results